Arbutus Loses Key European Patent in Moderna Dispute
Arbutus Biopharma shares dropped 16% after losing European patent dispute with Moderna. The biotech plans to appeal the ruling that affects ongoing litigation.
/ 907 items
#Healthcare↓
Goldman Sachs Upgrades BioNTech to Buy, Sees Strong Cancer Therapy Potential
Goldman Sachs raises BioNTech to Buy, citing its strong position in oncology and upcoming 2026 data that could boost new cancer therapies.
FDA Grants Orphan Drug Status to (Z)-Endoxifen for Duchenne Muscular Dystrophy
Atossa Therapeutics receives FDA orphan drug designation for (Z)-endoxifen to treat Duchenne muscular dystrophy, a rare genetic muscle-wasting disease.
ImmunityBio Stock Soars 100% in 2026 on Blockbuster Drug Sales
ImmunityBio shares surge with 10-day winning streak as ANKTIVA cancer drug revenue jumps 700% to $113M. Saudi approval and analyst targets signal more upside ahead.
Texas Pharmacy Sues Eli Lilly and Novo Nordisk Over GLP-1 Weight-Loss Drug Access
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
Sanofi Pursues Enhanced Bid for US Biotech Ocular Therapeutix
French pharma giant Sanofi is preparing an improved takeover offer for Ocular Therapeutix after its initial $16-per-share proposal was rejected by the biotech's board.